30 cent target, page-13

biotechtrader

There's no doubt that Bisantrene showed a lot of promise with AML and hopefully those results can be replicated (improved on?). Some concern over toxicity - quite a few years have passed, FDA standards might have changed. I'm just playing Devil's advocate, but the submission to the FDA was quite some time ago and we don't don't know whether RAC has addressed the FDA's questions yet. They've gone quiet on this one and I didn't get a reply when I enquired about whether RAC was still working on their reply.


Cheers